Viramune

Viramune Drug Interactions

nevirapine

Manufacturer:

Boehringer Ingelheim

Distributor:

DKSH
Full Prescribing Info
Drug Interactions
The following data were generated using the VIRAMUNE immediate-release tablets but are expected to apply to all dosage forms.
Nevirapine has been shown to be an inducer of hepatic cytochrome P450 metabolic enzymes (CYP3A, CYP2B) and may result in lower plasma concentrations of other concomitantly administered drugs that are extensively metabolised by CYP3A or CYP2B (see Pharmacology: Pharmacokinetics under Actions). Thus, if a patient has been stabilised on a dosage regimen for a drug metabolised by CYP3A or CYB2B and begins treatment with nevirapine, dose adjustments may be necessary.
Viramune XR: Combining the following compounds with VIRAMUNE is not recommended: Efavirenz, rifampicin, ketoconazole; if not co-administered with low dose retonavir: Fosamprenavir, saquinavir, atazanavir.
The absorption of nevirapine is not affected by food, antacids or medicinal products which are formulated with an alkaline buffering agent.
The majority of the interaction data is presented as percent changes (geometric mean) with a 95% prediction interval (95% PI). (See Tables 10a, 10b, 10c and 10d.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image


Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Other Information: In vitro studies using human liver microsomes indicated that the formation of nevirapine hydroxylated metabolites was not affected by the presence of dapsone, rifabutin, rifampin, and trimethoprim/sulfamethoxazole. Ketoconazole and erythromycin significantly inhibited the formation of nevirapine hydroxylated metabolites. Clinical studies have not been performed.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in